Characterization of a human powered nebulizer compressor for resource poor settings
- Christopher J Hallberg†1, 4,
- Mary Therese Lysaught†2, 3,
- Christopher E Zmudka†5,
- William K Kopesky†5 and
- Lars E Olson†1Email author
© Hallberg et al.; licensee BioMed Central Ltd. 2014
Received: 29 January 2014
Accepted: 2 June 2014
Published: 16 June 2014
Respiratory disease accounts for three of the ten leading causes of death worldwide. Many of these diseases can be treated and diagnosed using a nebulizer. Nebulizers can also be used to safely and efficiently deliver vaccines. Unfortunately, commercially available nebulizers are not designed for use in regions of the world where lung disease is most prevalent: they are electricity-dependent, cost-prohibitive, and not built to be reliable in harsh operating conditions or under frequent use.
To overcome these limitations, the Human Powered Nebulizer compressor (HPN) was developed. The HPN does not require electricity; instead airflow is generated manually through a hand-crank or bicycle-style pedal system. A health care worker or other trained individual operates the device while the patient receives treatment.
This study demonstrates functional specifications of the HPN in comparison with a standard commercially available electric jet nebulizer compressor, the DeVilbiss Pulmo-Aide 5650D (Pulmo-Aide).
Pressure and flow characteristics were measured with a rotameter and pressure transducer, respectively. Volume nebulized by each compressor was determined by mass, and particle size distribution was determined via laser diffraction. The Hudson RCI Micro Mist nebulizer mouthpiece was used with both compressors.
The pressure and flow generated by the HPN and Pulmo-Aide were: 15.17 psi and 10.5 L/min; and 14.65 psi and 11.2 L/min, respectively. The volume of liquid delivered by each was equivalent, 1.097 ± 0.107 mL (mean ± s.e.m., n = 13) for the HPN and 1.092 ± 0.116 mL for the Pulmo-Aide. The average particle size was also equivalent, 5.38 ± 0.040 micrometers (mean ± s.e.m., n = 7) and 5.40 ± 0.025 micrometers, respectively.
Based on these characteristics, the HPN’s performance is equivalent to a popular commercially available electric nebulizer compressor. The findings presented in this paper, combined with the results of two published clinical studies, suggest that the HPN could serve as an important diagnostic and therapeutic tool in the fight against global respiratory health challenges including: tuberculosis, chronic obstructive pulmonary disease, asthma, and lower respiratory infections.
Respiratory disease is a leading cause of death worldwide. According to the World Health Organization, lower respiratory infections (LRIs), chronic obstructive pulmonary disease (COPD), and tuberculosis (TB) are major causes of mortality, ranking 3rd, 4th, and 11th respectively, killing 3.2, 3 and 1 million persons in 2011 . In low-income countries, LRIs are the leading killer and usually strike children under 5 years of age. Some estimate that in 2011, 64 million people suffered from COPD worldwide , with a profound effect on death and disability . TB is a leading cause of death among HIV-positive individuals and is co-epidemic with HIV in sub-Saharan Africa . By any measure, these three diseases are grave global health challenges.
At first glance, these three diseases share only the organ they impact. Etiology, diagnosis, treatment, and prevention strategies for these conditions are diverse in nature and technology. In addition to being diseases of the lung, they do share the populations they impact, namely the poor throughout low and middle-income countries, particularly in regions without access to primary health care. Many facets of poverty augment the incidence and mortality of these conditions. Health care for the poor is confounded by a lack of infrastructure and a dearth of healthcare providers. These factors suggest a need for a simple, appropriate solution, ideally a single technology platform that can address all these diseases.
Direct delivery of therapeutics to the lung tissue has long been a successful strategy . Inhaled aerosolized medicine targets the lung tissue while minimizing systemic side effects and has the potential to require less medicine. Technologies for direct delivery include various types of inhalers and nebulizers. The metered dose inhaler (MDI) is a standard technology for bronchodilator treatment of reactive airway diseases, like COPD and asthma. Dry powder inhalers (DPIs) have also been used to deliver a variety of drugs and are advantageous in some situations.
Nebulizers have been used widely as well . They have been used in the administration of bronchodilators and antibiotic delivery [5, 7–9]. In TB diagnosis, nebulized hypertonic saline is a successful way to obtain sputum samples for smear tests and other tests in individuals, especially as part of intensified case-finding in those who do not yet have a productive cough . Intriguingly, there is evidence that a new potential treatment for certain LRIs using nebulized hypertonic saline may prove effective [11, 12]. Nebulized vaccines, including the measles and measles-mumps-rubella vaccines, have been shown to produce an equivalent, and in some studies stronger, immune response than their injected counterparts, without the associated risk of blood-borne disease transmission [13, 14].
Each of these delivery technologies has advantages and disadvantages. MDIs are small and portable, but their effectiveness has been questioned because of problems in patient inhaler technique and the need for frequent re-training [15, 16]. This drawback could be amplified in regions where health professionals are already overburdened and unable to provide requisite training to patients. Use of valved spacers with MDIs lessens the importance of proper technique and improves lung deposition . Spacers, however, represent an additional cost and require periodic cleaning to remain functional, which lessen their attractiveness for use in resource poor settings. DPIs use the patient's inhalatory force to deliver medicines to the lower respiratory tract obviating the need for propellants. DPIs have noted limitations with regard to delivery system reliability and require special drug formulations to create the ideal particle diameter . Also inhalers, both DPIs and MDIs, are limited in the volume they can deliver and could never be used for certain applications, such as delivery of hypertonic saline solution, for example. Moreover, inhaler devices, particularly DPIs, each have different operating instructions, requiring significant investment in training by the implementing body for each of these technologies.
The nebulizer, however, could provide a single platform for diagnosing TB, treating COPD and LRIs, and delivering vaccines. Jet nebulizers have several distinct advantages over other aerosolized technologies: improved patient compliance, less patient training, and potentially lower per-treatment costs. Jet nebulizers have the benefit of being less likely to denature the therapeutics they deliver, in contrast to ultrasonic nebulizers [18, 19].
With respect to DPIs and MDIs, nebulizers have the ability to deliver substantial volumes of liquid treatments. The chief drawback of nebulizers is that they are less portable. Ultrasonic and vibrating mesh nebulizers are portable, but they are more expensive, have components that require more frequent replacement, and are not intended for continuous use, such as a clinical setting . In other words, they may not be particularly suited for developing contexts.
A key limitation of jet nebulizers in developing contexts is that they require significant amounts of electric power, on the order of 100 W. Regions where electricity is non-existent or unreliable experience increased incidence of respiratory diseases, for example, those caused by indoor air pollution [20, 21]. Ultrasonic and vibrating mesh nebulizers require less power than jet nebulizers, but their higher cost and need for battery recharging still exists. One reason why the jet nebulizer as a single-platform-multiple-use concept has not been explored in global respiratory health may be this requirement for electricity.
The Human Powered Nebulizer (HPN) was invented to address this problem. The HPN is a manual compressor that works with existing, inexpensive nebulizer mouthpieces. The purpose of this study was to compare the performance of the HPN to an electric nebulizer compressor on key performance measures: volume delivery, pressure and flow characteristics, and delivered particle size distribution. The present study complements two published clinical trials that have demonstrated equivalence between the HPN and an electric nebulizer for the production of sputum samples for TB diagnosis  and for the treatment of patients with mild to moderate asthma exacerbations .
Key to the administration of liquid medication deep into the lungs is the particle size distribution of aerosol particles coming from the nebulizer. A range of 1–5 microns in particle diameter has been suggested as maximizing deposition deep into the lungs . The nebulizer mouthpiece used in this study, the Hudson RCI Micro Mist, makes an aerosol from a jet of air that flows through a submersed orifice. Compared to other nebulizer mouthpieces, the output of the Micro Mist is relatively insensitive to changes in the angle of the mouthpiece, thus requiring less training. To ensure a consistent particle size distribution for this and many other nebulizer mouthpieces of this type, the velocity of air past the submersed orifice must be within a certain range. Therefore, the key design parameter of the jet nebulizer compressor is a constant specific airflow at a pressure sufficient to overcome the hydraulic resistance of the nebulizer mouthpiece itself.
Each piston has two inlet/outlets. A tee is connected to each inlet/outlet. On one end of the tee is a one-way valve, model 64048 (US Plastics, Lima, OH, USA) directed inward so that air can flow into the piston. The other end of the tee is connected to a one-way valve directed outward so that air can flow from the piston to the nebulizer mouthpiece. Connections were made with Tygon® tubing, model 5114 K54 (US Plastics, Lima, OH, USA). This outlet flow was directed through a flow regulator, model Y1-4 NPT (Gate LLC, Sebastian, FL, USA). The outflow from the flow regulator was then delivered to the nebulizer mouthpiece via the tubing supplied by the mouthpiece manufacturer. In order to generate the requisite flow rate using human power with the aforementioned pistons, gearing systems were selected to achieve an effective frequency of piston operation with minimal human exertion.
The bicycle version uses a standard bottom bracket pedal combination, gears and a chain connected to a modified bicycle frame that has been welded so as to secure the pistons in a stationary position. The length of the pedal crank was 18 cm, attached to a 36-tooth gear which drove a 13-tooth gear attached to a modified wheel hub, for a gear ratio of approximately 1:3 – every full turn of the pedal generated 3 piston strokes. A 5 cm plate was attached to the hub, and connected to the piston with a pin. This limited the travel of the piston, i.e., the effective lever arm on the piston, to 10 cm.
The hand-cranked version uses a direct gear system, with a 22 cm long handle connected to a two-gear system, models S1VS24-100 F1524 and S1VS24-025 F1516 (SDP/SI, New Hyde Park, NY, USA). The gears were connected to a custom-built crankshaft which then connected to the pistons. The gear ratio in this version was 1:4. For both the bicycle and hand cranked version, the force needed to operate the HPN was approximately 18 N, the equivalent energy expenditure required to pedal a bicycle at approximately 8 miles/hour.
In all comparison studies in this work, the HPN was compared to a DeVilbiss Pulmo-Aide 5650D compressor (DeVilbiss, Somerset, PA, USA). The nebulizer mouthpiece used was the Hudson RCI Micro Mist (Teleflex, Research Triangle Park, NC, USA). All experiments were conducted between 20 – 24°C at relative humidity between 50 and 60%.
Two configurations were used for measuring pressure and flow. In the first configuration, airflow was measured using a variable area rotameter, model MR3000-30 lpm (Key Instruments, Trevose, PA, USA) without the nebulizer mouthpiece in place. The outflow of the rotameter was open to atmospheric pressure. The output of the nebulizer compressors was connected to the rotameter with Tygon tubing. In the second configuration, upstream pressure was measured using a pressure transducer, model PX139-03004 V (Omega Engineering, Stamford, CT, USA) with output pressure range between 0 and 30 psi. The pressure transducer output was collected using an A/D converter, model NI USB-6008 (National Instruments, Austin, TX, USA) and stored on a computer. Pressure was measured both with and without the nebulizer mouthpiece downstream in the airflow circuit. The nebulizer mouthpiece was connected to the nebulizer compressor with a 120 cm length of Tygon tubing. The tubing was cut half the distance between the mouthpiece and the compressor and a plastic tee was inserted. The third branch of the tee was connected to the pressure transducer with a 15 cm piece of Tygon tubing.
Volume nebulized measurements
For these experiments, 5 mL of water was placed in the nebulizer mouthpiece cup and weighed. The nebulizer compressor under test was operated for 5 minutes. The mouthpiece was held stationary, in a vertical position, for the duration of the test. After the operating period, the nebulizer mouthpiece was weighed again and the difference in mass and, thus, volume was recorded.
Particle size distribution measurements
Particle size distribution was measured using the hand-crank HPN design and the DeVilbiss compressor with a Malvern Mastersizer S laser diffraction particle size analyzer (Malvern Instruments Ltd, Malvern, UK). The output of the Micro Mist nebulizer mouthpiece was positioned 2.5 cm from the laser beam of the Mastersizer. The outflow of the mouthpiece was oriented vertically so that the narrowest part of the mist interacted with the laser light. Without the force of a patient’s inspiratory flow, the output of the nebulizer mouthpiece formed a swirling cloud of particles near the output of the mouthpiece of the device. To accurately determine particle size, air from a tank was passed through one end of the mouthpiece at 15 L/min to propagate the mist across the laser path. Particle size was determined with both 2.5 and 5 mL volumes of normal saline in each of the mouthpieces to determine the effect of fill volume on particle distribution. Particle size distribution using either the HPN or the DeVilbiss compressor was recorded. The Mastersizer reports droplet size in volume median (Dv0.5) values: the diameter of the delivered particle at which 50% is smaller than the indicated size. Dv0.5 can be assumed to be equivalent to the mean mass aerodynamic diameter (MMAD) determined by cascade impactor particle sizing if the density of particles is constant across the particle distribution, as is the case in this study. For ease of comparison to other values in the literature, particle size will be reported as MMAD.
Nebulizer fill volume
5.38 ± 0.040
5.36 ± 0.058
5.40 ± 0.025
5.42 ± 0.016
The idea of a nebulizer designed for rural or remote regions is not new. The classic Mexican device for aerosolized vaccine delivery is perhaps the best known . One physician who was practicing medicine in El Salvador during its civil war in the 1980’s developed a device based on a large syringe-like pump (personal communication with Fausto Cea Gil, M.D., San Salvador, 2010). The initial HPN prototypes were also simple, and lacked necessary design features that make the HPN equivalent to the Pulmo-Aide model in an effort to keep the design affordable. Other hand-powered devices have also been manufactured; DeVilbiss offers a nebulizer mouthpiece driven by a squeeze bulb. Although it generates particles of respirable size, 5 μm MMAD, the rate of volume delivery is far less than modern electric compressors. Cameron-Price manufactures a foot pump nebulizer compressor with output characteristics similar to the Pulmo-Aide when operated properly. However, this model does not have a flow regulator to ensure proper flow rate and as a result, high variability in performance is likely .
The goal of the HPN project and of this study was to design a nebulizer compressor that was low cost. The project also aimed to develop a device that conformed to a commonly-used commercially available electric model with typical output characteristics. The hypothesis of the study presented here was that the HPN would perform equivalent to a commercially available electric nebulizer compressor, and the evidence from this study consistently supports that hypothesis. Based on the data presented here, the HPN performs equivalently to the Pulmo-Aide, which was selected for comparison in our study because it is a commonly used, well characterized, compressor model.
The small differences in flow and pressure values are well within range of other commercially available nebulizer compressors. Smith et al. presented a performance comparison of 23 different models of jet nebulizer compressors . In this study, the mean particle diameter varied from 2.6 to 10.2 micrometers. Flow ranged from 3 to 8 L/min, and the volume of drug delivery also varied quite widely. This study is instructive in the design of the current work in two ways. First, the HPN functions within the particle size range offered by electric compressors and nebulizer mouthpiece pairings evaluated by Smith et al. Second, the variance in performance between electric nebulizer systems suggests that treatment efficacy may vary greatly in actual patients. The goal of the HPN was to be as close to the ideal as possible, i.e., between 1 and 5 micrometers for particle size as well as having the same flow rate and delivery volume.
To design and build a low-cost nebulizer compressor that provides performance equivalent to the best available devices, but does not require electricity—and would be operated by human effort—levied additional design constraints for performance including operational feedback, user effort, and user perception. Yet performance criteria are not the only considerations relevant to the development and assessment of a device like the HPN; additional design parameters for developing contexts must include considerations of device implementation.
Respiratory disease remains a leading cause of death and disability in low and middle income countries. Nebulizers are essential tools in the management and diagnosis of respiratory pathology but their use has been limited to areas with access to electricity. The reported data suggest that the HPN’s performance is equivalent to a popular commercially available electric nebulizer compressor. Consequently, the HPN could serve as an important diagnostic and therapeutic tool in the fight against global respiratory health challenges including: chronic obstructive pulmonary disease, asthma, tuberculosis and lower respiratory infections.
The authors wish to thank Richard F. Karuhn and Lisa Jandecek of Particle Technology Labs for their expert guidance and generous donation of staff and equipment time.
- World Health Organization: The top 10 causes of death; Fact Sheet No 310. http://who.int/mediacentre/factsheets/fs310/en/
- World Health Organization: Chronic Obstructive Pulmonary Disease; Fact Sheet No 315. http://who.int/mediacentre/factsheets/fs315/en/
- Aït-Khaled N, Enarson DA, Ottmani S, Sony El A, Eltigani M, Sepulveda R: Chronic airflow limitation in developing countries: burden and priorities. Int J Chron Obstruct Pulmon Dis 2007, 2: 141–150.Google Scholar
- Nunn P, Reid A, De Cock KM: Tuberculosis and HIV infection: the global setting. J Infect Dis 2007,196(Suppl 1):S5–14.View ArticleGoogle Scholar
- Hickey AJ: Inhalation Aerosols: physical and biological basis for therapy. New York, NY: M. Dekker; 1996.Google Scholar
- Jacob B, O'Driscoll BR, Dennis JH: Practical Handbook of Nebulizer Therapy. Taylor & Francis; 2003.Google Scholar
- Palmer LB: Aerosolized antibiotics in the intensive care unit. Clin Chest Med 2011, 32: 559–574. 10.1016/j.ccm.2011.05.012View ArticleGoogle Scholar
- Geller DE: Aerosol antibiotics in cystic fibrosis. Respir Care 2009, 54: 658–670.View ArticleGoogle Scholar
- Luyt C-E, Combes A, Nieszkowska A, Trouillet J-L, Chastre J: Aerosolized antibiotics to treat ventilator-associated pneumonia. Curr Opin Infect Dis 2009, 22: 154–158. 10.1097/QCO.0b013e328322a006View ArticleGoogle Scholar
- Hepple P, Ford N, McNerney R: Microscopy compared to culture for the diagnosis of tuberculosis in induced sputum samples: a systematic review. Int J Tuberc Lung Dis 2012, 16: 579–588. 10.5588/ijtld.11.0617View ArticleGoogle Scholar
- Safdar A, Shelburne SA, Evans SE, Dickey BF: Inhaled therapeutics for prevention and treatment of pneumonia. Expert Opin Drug Saf 2009, 8: 435–449. 10.1517/14740330903036083View ArticleGoogle Scholar
- Al-Ansari K, Sakran M, Davidson BL, Sayyed El R, Mahjoub H, Ibrahim K: Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants. J Pediatr 2010, 157: 630–634. 634.e1 10.1016/j.jpeds.2010.04.074View ArticleGoogle Scholar
- Bennett JV, Fernandez de Castro J, Valdespino-Gomez JL, Garcia-Garcia M de L, Islas-Romero R, Echaniz-Aviles G, Jimenez-Corona A, Sepulveda-Amor J: Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. Bull World Health Organ 2002, 80: 806–812.Google Scholar
- Hardwell A, Barber V, Hargadon T, McKnight E, Holmes J, Levy ML: Technique training does not improve the ability of most patients to use pressurised metered-dose inhalers (pMDIs). Prim Care Respir J 2011, 20: 92–96. 10.4104/pcrj.2010.00088View ArticleGoogle Scholar
- Ulrik CS, Backer V, Søes-Petersen U, Lange P, Harving H, Plaschke PP: The Patient's Perspective: Adherence or Non-adherence to Asthma Controller Therapy? J Asthma 2006, 43: 701–704. 10.1080/02770900600925569View ArticleGoogle Scholar
- Pedersen S, Dubus JC, Crompton G: The ADMIT series–Issues in Inhalation Therapy. 5) Inhaler selection in children with asthma. Prim Care Respir J 2010, 19: 209–216. 10.4104/pcrj.2010.00043View ArticleGoogle Scholar
- Islam N, Gladki E: Dry powder inhalers (DPIs)—a review of device reliability and innovation. Int J Pharm 2008, 360: 1–11. 10.1016/j.ijpharm.2008.04.044View ArticleGoogle Scholar
- British Thoracic Society Nebulizer Review Group: Review: Nebulizer Therapy Guidelines. Thorax 1997, 52: S4–24.View ArticleGoogle Scholar
- Dolovich MB, Dhand R: Aerosol drug delivery: developments in device design and clinical use. Lancet 2011, 377: 1032–1045. 10.1016/S0140-6736(10)60926-9View ArticleGoogle Scholar
- Kammen DM, Kirubi C: Poverty, Energy, and Resource Use in Developing Countries. Ann N Y Acad Sc 2008, 1136: 348–357. 10.1196/annals.1425.030View ArticleGoogle Scholar
- Dunn AM, Darvell F, Wilson RSE: An evaluation of the foot pump as a driving source for nebulizer solutions. Br J Dis Chest 1985, 79: 172–176.View ArticleGoogle Scholar
- Kranzer K, Olson L, van Schaik N, Radithalo E, Hudson E, Panigrahi P, Bekker LG: Quality of induced sputum using a human-powered nebuliser in a mobile human immunodeficiency virus testing service in South Africa. Intl J Tuberc Lung Dis 2011,15(8):1077–81. 10.5588/ijtld.10.0684View ArticleGoogle Scholar
- Hallberg CJ, Lysaught MT, Najarro RA, Cea Gil F, Villatoro C, de Uriarte AC D, Olson LE: Treatment of Asthma Exacerbations with the Human Powered Nebulizer: A Randomized Parallel-Group Clinical Trial. Prim Care Resp J 2014. in pressGoogle Scholar
- Smith EC, Denyer J, Kendrick AH: Comparison of twenty three nebulizer/compressor combinations for domiciliary use. Eur Respir J 1995, 8: 1214–1221. 10.1183/09031936.95.08071214View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.